USPTO serial 76113584
Reviewed by CopyMark Law Group
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Viviana Amzel
VIVIANA AMZEL EPIGENESIS PHARMACEUTICALS, INC7 CLARKE DRCRANBURY, NJ 08512UNITED STATES| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Describing and providing medical diagnostic and pharmaceutical preparations with anti-sense oligonucleotides for testing, preventing, and therapeutically treating human and non-human animal respiratory ailments that may be associated with hyper-sensitivity or hyper-responsiveness to adenosine, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in many cases are adenosine receptor associated symptoms; pharmaceutical preparations for the treatment of airway and pulmonary diseases and conditions, such as asthma, pulmonary vascoconstriction, inflammation, allergies, impeded respiration, Acute Respiratory Distress Syndrome (ARDS), renal damage and failure, ischemia, resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating SupraVentricular Tachycardia (SVT), adenosine stress tests, infantile Respiratory Distress Syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vascoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, etc., as well as all other metastatic cancers, e.g., cancers which metastasized to the lung(s), breast, liver and prostate | SECTION 8 - CANCELLED | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| May 16, 2009 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Oct 1, 2007 | CFIT | CASE FILE IN TICRS | — |
| Aug 27, 2002 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 4, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 15, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Jan 28, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 27, 2001 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 22, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2001 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 16, 2001 | DOCK | ASSIGNED TO EXAMINER | — |